IDEMIA
25.3.2021 09:02:05 CET | Business Wire | Press release
This partnership increases value for eService providers and citizens by offering strong mobile authentication and digital signatures. It enables reliable and convenient access to eServices regardless of location, by turning a citizen’s smartphone or tablet into a highly-secure authentication and signing device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005345/en/
Cybernetica’s technology, SplitKey, complements IDEMIA’s digital ID solutions based on biometrics in order to better meet the diverse needs of governments with a mobile-app and cloud-based approach. These solutions enable secure authentication and qualified signatures in accordance with the EU regulation (eIDAS).
SplitKey uses innovative cryptographic solutions. To ensure security, authentication and signing are only successful when all parts of the person’s credentials (i.e. private keys) - stored between their smart device and the SplitKey host's server - act together across the devices. SplitKey currently assures 70 million transactions a month all over Europe, made by millions of users across hundreds of eServices.
IDEMIA’s digital ID solution, IDway, facilitates ID issuance and authentication and is customizable to meet specific national technical and regulatory requirements. Governments can issue an airtight digital ID based on a national database or ID document.
“We welcome the synergy of combining Cybernetica ’s unique expertise in developing digital identity technology with IDEMIA ’s outstanding position around the world. We are focused on delivering technology that helps people securely interact in an increasingly connected world. Our partnership with IDEMIA, the global leader in Augmented Identity, is a step towards the widespread use of secure mobile authentication and digital signing services globally,” said Oliver Väärtnõu , Chairman of the Management Board at Cybernetica.
”We are delighted to partner with Cybernetica, whose unique role in building the eGovernance ecosystem in Estonia is a global reference. Establishing a secure authentication and eSignature via smartphones is becoming increasingly sought after by many citizens. Cybernetica’s technology fits perfectly with our Digital ID solutions so that we can always support governments as they roll out trusted ID systems among their populations.” said Pierre Lelièvre , IDEMIA Senior Vice President Digital Identity - Public Security & Identity.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About Cybernetica
Cybernetica has over 20-years of experience in building future-proof products that rely on research and development. The company has had an integral role in building Estonia’s unique e-governance ecosystem, notably the digital identity and secure data exchange infrastructure, and the secure internet voting system. In the digital identity space, the company developed the concept for the original ID-card infrastructure along with supporting legislation in Estonia and has consulted various governments on the topic. SplitKey technology was created by combining Cybernetica’s experiences in the digital identity domain and strength in research and development in cryptography. Currently Cybernetica’s technologies are used in 35 countries all over the world, from Asia to North America to the Caribbean and more.
For more information on Cybernetica, visit cyber.ee / Follow @cybernetica on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release
An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p
Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse
Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
